As of 2026-04-28, the Intrinsic Value of Harvard Bioscience Inc (HBIO) is (222.73) USD. This HBIO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 6.83 USD, the upside of Harvard Bioscience Inc is -3,361.10%.
The range of the Intrinsic Value is (336.10) - (170.68) USD
Based on its market price of 6.83 USD and our intrinsic valuation, Harvard Bioscience Inc (HBIO) is overvalued by 3,361.10%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (336.10) - (170.68) | (222.73) | -3361.1% |
| DCF (Growth 10y) | (171.17) - (310.38) | (215.35) | -3253.0% |
| DCF (EBITDA 5y) | (149.00) - (194.23) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (153.97) - (197.48) | (1,234.50) | -123450.0% |
| Fair Value | -63.42 - -63.42 | -63.42 | -1,028.59% |
| P/E | (273.99) - (294.54) | (288.26) | -4320.4% |
| EV/EBITDA | 13.69 - 35.37 | 23.01 | 236.8% |
| EPV | 14.76 - 18.76 | 16.76 | 145.4% |
| DDM - Stable | (88.67) - (251.24) | (169.96) | -2588.4% |
| DDM - Multi | (78.75) - (180.30) | (110.39) | -1716.3% |
| Market Cap (mil) | 30.53 |
| Beta | 1.96 |
| Outstanding shares (mil) | 4.47 |
| Enterprise Value (mil) | 57.79 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.28% |
| Cost of Debt | 7.43% |
| WACC | 8.74% |